Session » Quality Measures and Quality of Care Poster Session (ARHP): Clinical Practice/Patient Care

Date: Monday, November 9, 2015

Time: 9:00AM-11:00AM

Meeting: 2015 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1493

Adherence in Patients Who Are on Stable Doses of Methotrexate

9:00AM-11:00AM: Abstract Number: 1490

Can Patients Forget Their Artificial Joint after Arthroplasty?

9:00AM-11:00AM: Abstract Number: 1486

Comparative Study of Instruments to Assess Disease Activity in Fibrolyalgia

9:00AM-11:00AM: Abstract Number: 1491

Effects of Drug Induced Toxicity on Patient Reported Outcomes in Early Rheumatoid Arthritis Treated-to-Target Using Conventional Triple DMARD Therapy

9:00AM-11:00AM: Abstract Number: 1498

Engaging Clinic Staff in Work System Redesign to Adapt a Hypertension Protocol for Rheumatology

9:00AM-11:00AM: Abstract Number: 1488

Following the American College of Rheumatology Quality Guidelines Can Enhance the Safety of Rheumatoid Arthritis Patients Treated with Disease Modifying Drugs

9:00AM-11:00AM: Abstract Number: 1492

Implementation in Clinical Practice of a Medication Assessment Tool Specific for Rheumatoid Arthritis, Rhmat

9:00AM-11:00AM: Abstract Number: 1497

Panlar Consensus on Hand, Hip and Knee OA

9:00AM-11:00AM: Abstract Number: 1499

Patients Who Take Many Medications for Their Fibromyalgia Symptoms at the Initial Office Visit Tend to Have a Worse Clinical Course

9:00AM-11:00AM: Abstract Number: 1495

Person-Centred Care Can Help Patients to Become More Effective Consumers in the Use of Health Information Than Regular Care – an RCT in Patients with Arthritis Undergoing Biological Therapy

9:00AM-11:00AM: Abstract Number: 1489

Promoting Smoking Cessation Among Rheumatoid Arthritis Patients: What Motivations and Barriers Are Reported after Being Offered a Smoking Cessation Intervention?

9:00AM-11:00AM: Abstract Number: 1494

The Role of a Nurse-Led Clinic in the Assessment and Prevention of Cardio-Vascular Risk

9:00AM-11:00AM: Abstract Number: 1487

Tocilizumab in Combination with Methotrexate in the Treatment of Rheumatoid Arthritis in Patients Who Have Failed to Disease-Modifying Antirheumatic Drugs: Long Term Results of the Brazilian Cohort

9:00AM-11:00AM: Abstract Number: 1496

Uncovering and Addressing Issues Related to Medication Adherence Among Patients with Rheumatic Diseases: A Patient Navigator Pilot Program

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].